'Treat-to-target': a call for earlier targeted intervention in asthma.
Couillard S. et al, (2025), J Allergy Clin Immunol Pract
Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies.
Pavord ID. et al, (2025), Pulmonary therapy
Treatable Trait Guided Asthma Management: A Feasibility Study
Fingleton J. et al, (2025), Respirology
Cough Reflex Hypersensitivity: A Common and Important Treatable Trait.
Pavord ID. and Gibson PG., (2025), The journal of allergy and clinical immunology. In practice, 13, 499 - 500
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
Lavoie G. et al, (2025), Thorax, 80, 113 - 116
Treatable Traits in Patients with Obstructive Lung Diseases in a Well-Established Asthma/COPD Service for Primary Care.
Dijk L. et al, (2025), International journal of chronic obstructive pulmonary disease, 20, 1189 - 1201
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment.
Lavoie G. et al, (2024), Thorax
Biologics in Asthma: Role of Biomarkers.
Lavoie G. and Pavord ID., (2024), Immunology and allergy clinics of North America, 44, 709 - 723
Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma.
Pavord ID. et al, (2024), The journal of allergy and clinical immunology. In practice
IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.
Luo J. et al, (2024), Mucosal immunology, 17, 524 - 536
Navigating uncertainty: asthma biologics during pregnancy.
Howell I. et al, (2024), The Lancet. Respiratory medicine
CHARACTERIZATION OF MODERATE AND SEVERE ASTHMA EXACERBATIONS IN THE CAPTAIN STUDY.
Oppenheimer J. et al, (2024), J Allergy Clin Immunol Pract
Blood eosinophils and lung function loss: from passive prediction to active prevention?
Ramakrishnan S. et al, (2024), European Respiratory Journal, 63, 2400812 - 2400812
The Rebirth of Lebrikizumab for Airway Disease.
Pavord ID., (2024), The journal of allergy and clinical immunology. In practice, 12, 1225 - 1227
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A. et al, (2024), Respiratory medicine, 224
Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.
Bourdin A. et al, (2024), The journal of allergy and clinical immunology. In practice, 12, 809 - 823